Testing pegozafermin for MASH and liver fibrosis
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a liver biopsy confirming MASH (a type of fatty liver disease with inflammation) and moderate to advanced scarring (fibrosis stage F2 or F3).
- Your body mass index (BMI) must be 25 or higher (or 23 or higher if you are of Asian descent).
- You cannot have other chronic liver diseases (like hepatitis B or C) or cirrhosis (severe scarring).
- You cannot have type 1 diabetes or poorly controlled type 2 diabetes.
- Your liver enzyme levels (ALT and AST) must be below 250 U/L (checked by a blood test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.